Dutasteride
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
High-potency DHT suppression for male-pattern hair loss, finasteride non-response, TRT/AAS hair preservation, and BPH symptom reduction.
Absolutely contraindicated in pregnancy — teratogenic to male fetuses even via skin contact with crushed capsules. Men must use condoms with partners of childbearing potential; no blood donation for 6 months after stopping.
High-potency DHT suppression for male-pattern hair loss, finasteride non-response, TRT/AAS hair preservation, and BPH symptom reduction.
Libido, erection, ejaculation-volume, gynecomastia, and dry-eye issues can occur. PSA suppression can mask prostate monitoring. Pregnancy exposure is a hard stop because DHT suppression can harm male fetal genital development. The 5-week half-life means benefits and side effects fade over months, not days.
The strongest oral 5ARI option: 93–95% serum DHT reduction vs finasteride's ~70%, with 80–95% AGA stabilization-or-regrowth response in the evidence summarized here. Best fit when finasteride is insufficient, testosterone load is high, or BPH and hair goals overlap.
High. Clinically superior to finasteride for both BPH and AGA outcomes in head-to-head data. Community reports strong stabilization and regrowth for AGA, particularly as a finasteride step-up.
Do not allow any woman who is or may become pregnant to handle crushed dutasteride capsules — fetal genital abnormalities from in-utero DHT suppression.
Intro
Dutasteride (brand: Avodart) is an oral synthetic 4-azasteroid and the only approved dual inhibitor of both type 1 and type 2 5-alpha-reductase (5AR) isoenzymes.
By irreversibly blocking both isoforms, it achieves near-complete suppression of dihydrotestosterone (DHT) — reducing serum DHT by 93–95% at the standard 0.5 mg/day dose, versus approximately 70% with finasteride (type 2-only). FDA approved in 2001 for symptomatic BPH, dutasteride is not FDA-approved for androgenetic alopecia (AGA) in the US, though it is approved for this indication in South Korea (2009) and Japan (2015) after GSK halted phase III AGA trials in 2002 for commercial rather than safety reasons.
The discovery of 5AR inhibition emerged from a 1974 natural experiment in the Dominican Republic, where men with a genetic defect in type 2 5AR (Imperato-McGinley syndrome) were found to have normal fertility but no prostate enlargement and no male pattern baldness — providing the biochemical rationale for the target. Dutasteride was subsequently developed through extensive structure-activity relationship studies against both cloned human isoenzymes by Stephen V. Frye.
The dual isoenzyme block is particularly relevant for androgenetic alopecia because scalp DHT is synthesized locally within hair follicles by both type 1 and type 2 5AR — not solely from circulating serum DHT. Finasteride's type-2-only inhibition leaves significant local scalp DHT production via the type 1 pathway, which is why dutasteride consistently outperforms finasteride for AGA, especially in men on exogenous androgens with high testosterone substrate. At supraphysiologic testosterone levels (e.g., 2000 ng/dL on AAS), dutasteride at 1mg/day drives serum DHT below detectable limits.
Dutasteride has an unusually long elimination half-life of approximately 5 weeks (35 days), making it the most pharmacologically persistent 5ARI. All dosing frequencies — daily, EOD, 3×/week, twice-weekly — converge to equivalent steady-state DHT suppression. Stopping dutasteride results in a gradual 3–5 month DHT rebound rather than the rapid rebound seen with finasteride.
Observed Effects
In androgenetic alopecia, dutasteride produces 5–11% hair regrowth at 6 months with an 80–95% response rate (stabilization or regrowth).
Head-to-head vs finasteride in meta-analysis of 6 RCTs (n=2,041): significantly greater IPSS improvement (MD −0.86, 95% CI −1.62 to −0.11, p=0.02) and greater PSA reduction (MD −0.13, p=0.03), with equivalent prostate volume, Qmax, and adverse event outcomes.
For BPH across 9 pooled RCTs (Park & Choi 2014 meta-analysis): IPSS improvement Δ= −1.78, peak urinary flow Qmax Δ= +1.27 mL/s, total prostate volume reduction Δ= −17.40 cm³. In the 6,460-patient meta-analysis (Wu et al. 2014): symptom score improved by 1.98, Qmax increased by 1.16 mL/s, prostate volume reduced by 13.86 mL, AUR risk reduced by 65% (OR 0.35). These improvements were maintained through 4 years of open-label extension without new safety signals.
Hormonal effects are predictable and clinically relevant: serum testosterone increases 19–26% (vs ~15% with finasteride) due to substrate accumulation when DHT synthesis is blocked. Estradiol rises proportionally through aromatization of elevated testosterone. DHT drops to 6–7% of baseline at 0.5mg/day; below detection limits at 1mg/day even at testosterone 2000 ng/dL. PSA decreases approximately 50% at 6 months — important context for prostate cancer surveillance. Combination with tamsulosin (CombAT trial) is superior to either monotherapy for BPH symptom management.
Field Reports
Across 8 first-person reports spanning 2+ years of use, community experience is generally positive for AGA with a well-understood adverse effect profile.
Regrowth outcomes: Multiple users report complete stabilization within 3–6 months and meaningful regrowth by 12–24 months. A 2-year user who transitioned from finasteride after 2 months of insufficient response achieved significant regrowth including full hairline restoration. A 30-year-old on 6 months 0.5mg/day reported hair loss stopped completely with some regrowth. A 31-year-old on dutasteride + minoxidil reported slight libido decrease but significant regrowth.
Initial shedding: One user documented the shed phase precisely — escalation from 60–80 hairs/day to 120–150 hairs/day at weeks 2–3 before eventual stabilization. This user ultimately discontinued due to severe dry eyes (an uncommon adverse effect) and experienced cumulative hair loss from both the shed and post-discontinuation DHT rebound. The shed is widely understood in the community as a temporary transitional effect, not treatment failure.
Paradoxical sexual improvement: A German user who had experienced sexual dysfunction on finasteride reported improved erection quality and orgasm intensity after switching to dutasteride. The mechanism is plausible — the greater testosterone elevation on dutasteride (vs finasteride) can enhance libido and erectile function in men where the T/E2 ratio improves. Community bloodwork reports consistently show elevated T, elevated E2, near-zero DHT, and normal liver/lipid values.
Timeline expectations: Community consensus is 3–6 months for stabilization, 12+ months for measurable regrowth, and 24 months for full assessment. Users who stopped before 12 months frequently report underestimating their results in retrospect.
Community Consensus
Dutasteride occupies a specific and well-defined niche in the fitness and TRT community: it is the preferred 5ARI for men using exogenous androgens who want to protect their hair.
The central insight is practical rather than cosmetic: scalp DHT is locally synthesized through both type 1 and type 2 5AR, so finasteride's type-2-only inhibition can be insufficient when testosterone substrate is high.
Community practice is most developed around three decisions: when to step up from finasteride, how to overlap during the transition, and what to pair with dutasteride for growth stimulation. The common finasteride-to-dutasteride transition uses a 4-8 week overlap to avoid a DHT coverage gap while dutasteride accumulates. The common maximal AGA stack is dutasteride plus minoxidil plus microneedling, because those tools cover DHT suppression, growth-phase stimulation, and wound-healing growth-factor signaling.
The consensus is bullish but bounded. Dutasteride is treated as a stronger band-aid for DHT-driven loss, not a cure for genetic susceptibility. The community generally accepts less-frequent dosing because the half-life is so long, but splits on whether that same long half-life is an advantage or liability: it makes coverage stable and missed doses irrelevant, but side effects and off-ramp problems can drag on for months.
Escalating to 1mg/day during heavy AAS blasts is a community practice rather than controlled clinical guidance. It is mechanistically defensible from the article's below-detection DHT claim at 1mg/day in very high-testosterone contexts, but it should stay labeled as a high-androgen-load tactic rather than ordinary AGA dosing.
Risks & Monitoring
Decreased libido, erectile dysfunction, ejaculation disorders (reduced volume, watery semen), and gynecomastia are the primary documented adverse effects.
In the AGA-specific sexual dysfunction meta-analysis (Lee et al., 15 RCTs, 4,495 subjects), dutasteride carried a 1.37-fold sexual dysfunction risk (95% CI 0.81–2.32) — importantly, this confidence interval includes 1.0, meaning the increase was NOT statistically significant vs placebo. By contrast, finasteride showed a statistically significant 1.66-fold risk. In head-to-head BPH meta-analysis, libido decrease (p=0.39) and impotence (p=0.17) were equivalent between dutasteride and finasteride. These events are elevated vs placebo but modestly in absolute terms, and long-term use over 4 years did not increase rates beyond year 1.
Initial dutasteride shed is common at weeks 2–3 of treatment — one documented case escalated from 60–80 hairs/day to 120–150 hairs/day before stabilizing. This represents follicle synchronization into telogen phase and is not a sign of treatment failure. Most users who persist through the shed see the best long-term outcomes.
PSA suppression by approximately 50% at 6 months requires doubling of all measured PSA values during dutasteride use for accurate prostate cancer surveillance. Failure to account for this can mask rising PSA from developing malignancy.
Rare individual reports include severe dry eyes leading to discontinuation (one documented community case). Post-discontinuation rebound shed occurs as DHT returns to normal over 3–5 months after stopping.
Teratogenicity is the most serious absolute contraindication: dutasteride causes serious genital abnormalities in male fetuses via in-utero DHT suppression. Even skin contact with crushed capsules is hazardous. Men must use condoms with partners of childbearing potential and cannot donate blood for 6 months after last dose.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Useful baseline for AGA/TRT/AAS users who want to verify response; at 6-12 weeks serum DHT should drop to <5% of baseline at 0.5mg/day. Not mandatory for every uncomplicated prescription user.
Dutasteride causes a 19-26% testosterone rise. Baseline is most useful when TRT/AAS dosing or libido side-effect attribution matters. Recheck around 3 months if symptoms or concurrent androgen changes make interpretation difficult.
E2 rises proportionally with testosterone substrate elevation. Elevated E2 can contribute to gynecomastia and libido changes; this is especially relevant for men on concurrent TRT or AAS.
Dutasteride suppresses PSA by ~50% at 6 months. Baseline is required for BPH users, men over 40, or anyone being followed for prostate cancer risk. Double measured PSA values during treatment.
Community bloodwork confirms normal lipids on dutasteride. Baseline appropriate given long-term use and T/E2 ratio shift.
Confirms HPG axis function. In men not on TRT, substrate accumulation affects feedback. Useful baseline if sexual side effects emerge.
Dutasteride is extensively metabolized via CYP3A4/CYP3A5. LFT baseline appropriate for long-term users, especially those on concurrent hepatically-loaded compounds.
Avoid With
Do not combine Dutasteride with the following. Sorted highest-severity first.
Why:Dutasteride absolutely inhibits DHT synthesis required for normal male fetal genital development. In-utero exposure via placental transfer or even skin contact with crushed tablets causes serious genital abnormalities.
What to do:Men must use condoms with partners of childbearing potential. Women must not handle crushed dutasteride capsules. No blood donation for 6 months after stopping dutasteride.
Why:Dutasteride is extensively metabolized by CYP3A4 and CYP3A5. Strong CYP3A4 inhibitors increase dutasteride plasma concentrations and extend effective half-life, potentially amplifying adverse effects.
What to do:Monitor for increased sexual adverse effects and gynecomastia when combining. No specific dose adjustment protocol established.
Why:Limited case reports suggest dutasteride can affect INR in patients on warfarin. Mechanism not fully characterized.
What to do:Monitor INR when initiating or stopping dutasteride in anticoagulated patients.
Why:Dutasteride already inhibits both isoenzymes that finasteride targets (type 2) plus type 1. Ongoing dual-5ARI use is pharmacologically redundant and adds adverse effect exposure without benefit.
What to do:Short overlap during finasteride-to-dutasteride transition (4–8 weeks) is intentional and appropriate. Ongoing concurrent dual use is not.
Protocols By Goal
Hair loss prevention during TRT: Start dutasteride at TRT initiation or at first signs of AGA acceleration. 0.5mg/day or 0.5mg twice-weekly. Stack with minoxidil 5% topical if AGA is moderate. Baseline T, DHT, E2; recheck at 3 months.
Finasteride non-responder: Transition using overlap protocol — take both finasteride and dutasteride simultaneously for 4–8 weeks before discontinuing finasteride. Overlap prevents coverage gap during dutasteride's ramp to steady state (takes ~3–4 months). Expect possible transition shed at weeks 2–4. Assess new regimen at 12–24 months minimum.
Hair protection on aggressive AAS cycles: 0.5mg/day during cycle. Consider 1mg/day during blast if Norwood 2+ with aggressive pattern. Continue through PCT — the post-cycle hormonal flux is high-risk for rebound shed if 5ARI coverage lapses. Stack with minoxidil.
Maximum AGA combination: Dutasteride 0.5mg/day + minoxidil 5% topical (or 1–2.5mg oral) + microneedling 1×/week (0.5–1.5mm scalp). Three mechanistically distinct pathways: dutasteride suppresses DHT substrate, minoxidil stimulates follicle growth phase via K-channel opening, microneedling drives VEGF/PDGF growth factor release.
BPH standard: 0.5mg once daily; full response takes 3–6 months; maximum prostate volume reduction by 24 months. Combine with tamsulosin if insufficient symptom relief.
Dosing Details
Standard dose: 0.5 mg orally once daily — FDA-approved for BPH; most studied dose for AGA. Achieves 93–95% serum DHT suppression and ~94% intraprostatic DHT suppression.
Frequency flexibility: The ~5-week half-life makes all dosing schedules pharmacokinetically equivalent at steady state. Daily, EOD, 3×/week, and twice-weekly (e.g., Mon/Thu) all produce the same steady-state DHT suppression. Twice-weekly is the dominant community protocol for AGA; daily is standard in BPH and in clinical AGA trials. Choose based on adherence preference — not efficacy considerations.
Entry protocol: Begin at 0.5mg twice-weekly for 4–8 weeks to assess tolerability before committing to daily use, or start daily from day one. Some practitioners favor the gradual entry approach given the long half-life and persistence of any side effects experienced.
AAS users: 0.5mg/day is standard during most cycles. Some community members increase to 1mg/day during heavy blast phases (>750mg/week testosterone equivalent) — community practice without controlled data support. At 1mg/day, DHT is driven to below-detectable limits even at 2000 ng/dL testosterone.
BPH: 0.5mg once daily; FDA-approved. Add tamsulosin for combination therapy per CombAT trial evidence if monotherapy is insufficient.
Stacks & Alternatives
Complementary mechanism — dutasteride suppresses DHT-driven follicle miniaturization; minoxidil stimulates growth phase via potassium channel opening. The most evidence-supported AGA combination.
Blocks androgen receptor at the scalp follicle level for any residual DHT or testosterone. Dutasteride reduces DHT substrate; RU58841 blocks receptor binding. Dual-mechanism stack for aggressive AGA or high-androgen-load contexts. Community use only — no clinical approval.
Induces VEGF, PDGF, and wound-healing growth factor release. Mechanistically complementary — addresses the growth stimulation pathway independently of DHT suppression.
For BPH: CombAT trial shows dutasteride + tamsulosin combination is superior to either monotherapy for IPSS, Qmax, and health status. Level 1 evidence.
Alternatives
Stack Cost
Moderate tax: dutasteride does not add injection or organ-toxicity burden, but it occupies the DHT-suppression lane for months, changes T/E2/PSA interpretation, and creates absolute pregnancy-handling constraints.
recommendedPanels requires baseline DHT, testosterone, estradiol, PSA, lipids, LH/FSH, and LFTs; practicalConsiderations emphasizes PSA interpretation because measured PSA should be doubled during treatment.
adverseEffects and practicalConsiderations describe teratogenicity as the absolute contraindication: male fetal genital development depends on DHT, and even crushed-capsule skin contact is hazardous during pregnancy.
stackingConflicts flags strong CYP3A4 inhibitors and anticoagulant monitoring as caution-level issues, while ongoing finasteride is redundant rather than synergistic.
The article frames dutasteride as a long-horizon AGA commitment: initial shed can occur at weeks 2-3, response assessment takes at least 12 months, and abrupt stopping can trigger a 3-5 month DHT rebound with shed.
- ·Counts as the 5-alpha-reductase/DHT-suppression layer; do not maintain finasteride concurrently except for the article's 4-8 week transition overlap.
- ·In TRT or AAS hair-preservation stacks, treat dutasteride as the hair-protection base and add minoxidil or microneedling only for complementary growth-pathway support.
- ·Any stack that changes testosterone, estradiol, libido, or prostate monitoring must account for dutasteride's expected 19-26% testosterone rise, proportional estradiol shift, and PSA suppression.
- ·Do not use when a partner is pregnant or may become pregnant unless the condom, handling, and blood-donation restrictions in the article are workable.
- ·Baseline DHT, total testosterone, sensitive estradiol, and PSA before treatment, with follow-up interpretation around the 3- to 6-month window.
- ·PSA interpretation rule for men on treatment: measured PSA values need correction because the article notes roughly 50% suppression by 6 months.
- ·Pregnancy-handling precautions: condoms with partners of childbearing potential, no handling of crushed capsules by pregnant women, and no blood donation for 6 months after stopping.
- ·Long-timeline adherence plan: initial shed counseling, 12-month minimum efficacy assessment, and a transition plan if stopping or switching to finasteride.
The dosing is simple and oral, but the user must understand long half-life, PSA correction, pregnancy handling, and the difference between expected early shed and treatment failure.
- ·Partner is pregnant or may become pregnant and handling/condom precautions cannot be followed
- ·Severe anxiety about persistent side effects from a compound with a 5-week half-life
- ·Need for frequent stop-start experimentation
- ·Unresolved baseline sexual dysfunction or gynecomastia where attribution will be difficult
The article repeatedly emphasizes the approximately 5-week half-life and 3-5 month DHT rebound; stopping is not acutely dangerous, but the cosmetic and adverse-effect timeline is slow and hard to reverse quickly.
- ·DHT rebound over 3-5 months
- ·Post-discontinuation hair shed
- ·Persistent sexual or estrogen-related adverse effects while drug levels decay
- ·Loss of AGA protection during PCT or high-androgen periods
The article says initial shed is common and not treatment failure; counsel the user before starting and judge efficacy over 12-24 months.
Record baseline PSA and apply the article's correction rule that measured PSA should be doubled during dutasteride treatment.
Follow the article's hard precautions: no exposure for pregnant people, condom use with partners of childbearing potential, and no blood donation for 6 months after last dose.
Use baseline and follow-up T, DHT, and sensitive estradiol so the expected substrate shift is separated from TRT or AAS dose effects.
The article treats fetal male genital abnormalities from DHT suppression as the absolute contraindication and requires condom and handling precautions.
Dutasteride suppresses PSA by about 50% at 6 months, so cancer surveillance can be misread without baseline PSA and correction.
The article lists libido, ED, ejaculatory dysfunction, gynecomastia, and proportional estradiol rise as the practical adverse-effect cluster.
The approximately 5-week half-life means both benefits and side effects can persist for months after stopping.
Practical Setup
The ~5-week half-life is the single most clinically important pharmacokinetic feature. Its consequences: any dosing frequency from twice-weekly to daily provides equivalent steady-state DHT suppression; missed doses have negligible pharmacodynamic impact; time to steady state is 3–4 months; after stopping, DHT returns to normal over 3–5 months; side effects experienced during treatment persist well beyond stopping.
For AAS users: dutasteride is effective even at supraphysiologic testosterone. Continue dutasteride through PCT — the post-cycle hormonal flux is high-risk for rebound shed if 5ARI coverage lapses at the same time DHT rebounds.
PSA monitoring: Any man over 40 initiating dutasteride should have a baseline PSA. Double all measured PSA values during treatment for accurate prostate cancer surveillance. This is clinically critical and often overlooked.
Pregnancy and handling: Men whose partners are or may become pregnant must use condoms during treatment. Do not donate blood for 6 months after stopping. Crushed or broken capsules must not be handled by pregnant women or women who may become pregnant — even dermal exposure is teratogenic.
Transitioning from finasteride: Use 4–8 week overlap to prevent DHT rebound shed during dutasteride's ramp-up phase. Transitioning off dutasteride: switch to finasteride rather than abrupt cessation if hair preservation is the goal — abrupt stop = 3–5 month DHT rebound = rebound shed.
Timeline management: Counsel users that the initial shed at weeks 2–3 is expected. Assessment of treatment efficacy requires a minimum of 12 months. Most treatment 'failures' in community experience were users who stopped before 12 months.
Mechanism Deep Dive
Dutasteride irreversibly binds to and inhibits both type 1 and type 2 5-alpha-reductase isoenzymes, blocking the intracellular conversion of testosterone to dihydrotestosterone (DHT).
DHT has approximately 5× higher androgen receptor (AR) binding affinity than testosterone; blocking its synthesis reduces androgen signaling in DHT-sensitive tissues including prostate, scalp follicles, and skin.
Isoenzyme specificity: Dutasteride is 45-fold more potent than finasteride against type 1 5AR and 2.5-fold more potent against type 2 5AR in vitro. Type 2 5AR predominates in prostate tissue; type 1 is the dominant isoenzyme in skin and scalp. Both are overexpressed in BPH and prostate cancer. Blocking both isoforms is essential for maximal scalp DHT suppression because type 1 5AR in scalp follicles continues DHT synthesis even when type 2 is fully inhibited by finasteride.
Scalp DHT local synthesis: Scalp DHT is synthesized locally within hair follicles by both type 1 and type 2 5AR enzymes — it is not solely derived from circulating serum DHT. This local synthesis pathway (particularly via type 1 5AR) is why finasteride can fail to halt AGA despite substantial serum DHT reduction. Dutasteride's dual inhibition suppresses both the systemic serum DHT contribution and the local follicle-level DHT synthesis.
DHT suppression: At 0.5mg/day: serum DHT reduced 93.7% (median, ARIA pivotal trials, p<0.001 vs placebo); intraprostatic DHT reduced 94% (double-blind Nature journal study, n=43). At 1mg/day: serum DHT below detection limits even at testosterone 2000 ng/dL. Strong correlation between serum and intraprostatic dutasteride concentrations (R²=0.73), indicating serum levels reliably reflect tissue exposure.
Testosterone and estrogen substrate effects: When DHT synthesis is blocked, testosterone substrate accumulates. Serum testosterone increases 19–26% on dutasteride (vs ~15% with finasteride). Elevated testosterone is available for aromatization, increasing estradiol proportionally. This T/E2 ratio shift is the predictable pharmacodynamic consequence and drives the need for hormonal monitoring.
Irreversible inhibition and pharmacokinetics: Dutasteride forms a covalent bond with 5AR isoenzymes — enzyme activity is restored only through new enzyme synthesis. Oral bioavailability ~60% (independent of food). Approximately 99% plasma protein bound (albumin and alpha-1 acid glycoprotein). Extensively metabolized by CYP3A4 and CYP3A5. Half-life approximately 5 weeks — the longest of any 5ARI. Time to steady state approximately 3–4 months.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
Dutasteride reduces serum DHT by 93-95% at the standard 0.5 mg/day dose, versus approximately 70% with finasteride.
The article gives the effect size but not the exact source trial metadata; apply to DHT suppression, not automatically to hair regrowth magnitude.
FDA approved dutasteride in 2001 for symptomatic BPH; AGA approvals occurred in South Korea in 2009 and Japan in 2015.
This is regulatory context, not an efficacy estimate; approval status differs by indication and country.
At supraphysiologic testosterone levels around 2000 ng/dL, dutasteride at 1 mg/day drives serum DHT below detectable limits.
The article does not provide controlled trial metadata for this high-androgen context; treat as community/mechanistic support, not standard BPH dosing evidence.
Dutasteride has an elimination half-life of approximately 5 weeks, with DHT rebound over 3-5 months after stopping.
The long half-life is pharmacokinetic context; it explains slow reversibility and does not by itself prove equivalent clinical outcomes at every schedule.
In androgenetic alopecia, dutasteride produces 5-11% hair regrowth at 6 months with an 80-95% response rate.
The article notes the strongest direct AGA meta-analysis was blocked during generation, so source metadata is incomplete and this should stay scoped to the cited AGA evidence base.
Head-to-head meta-analysis of 6 RCTs (n=2,041) found greater IPSS improvement (MD -0.86, 95% CI -1.62 to -0.11, p=0.02) and greater PSA reduction (MD -0.13, p=0.03), with equivalent prostate volume, Qmax, and adverse-event outcomes.
The endpoints are BPH/prostate outcomes and should not be generalized as direct AGA regrowth evidence.
Across 9 pooled RCTs, IPSS improved by -1.78, Qmax increased by +1.27 mL/s, and total prostate volume decreased by -17.40 cm3.
BPH symptom and prostate-volume effects do not directly translate to AGA or TRT hair-protection users.
In a 6,460-patient meta-analysis, symptom score improved by 1.98, Qmax increased by 1.16 mL/s, prostate volume reduced by 13.86 mL, and AUR risk reduced by 65% (OR 0.35).
This is BPH evidence; it supports urinary/prostate outcomes, not cosmetic hair response.
Serum testosterone increases 19-26%, estradiol rises proportionally, DHT drops to 6-7% of baseline at 0.5 mg/day, and PSA decreases approximately 50% at 6 months.
These pharmacodynamic shifts are central to lab interpretation; the article does not give one unified source for all hormone and PSA figures.
0.5 mg orally once daily achieves 93-95% serum DHT suppression and about 94% intraprostatic DHT suppression.
Intraprostatic DHT data is prostate-tissue evidence and should not be treated as direct scalp-follicle exposure measurement.
Daily, every-other-day, three-times-weekly, and twice-weekly dosing converge to the same steady-state DHT suppression because of the approximately 5-week half-life.
This is pharmacokinetic extrapolation from long half-life and should be separated from direct controlled efficacy comparisons of every schedule.
Entry protocol begins at 0.5 mg twice weekly for 4-8 weeks to assess tolerability before daily use.
The article frames this as a practical tolerability approach, not a controlled evidence-based superiority protocol.
Some community members increase to 1 mg/day during heavy blast phases above 750 mg/week testosterone equivalent.
The article explicitly says this practice lacks controlled data support; treat as community practice only.
Time to steady state is 3-4 months; after stopping, DHT returns to normal over 3-5 months and side effects can persist well beyond stopping.
This is pharmacokinetic consequence of the long half-life and irreversible 5AR inhibition; it is most relevant to reversibility and off-ramp planning.
Any man over 40 initiating dutasteride should have a baseline PSA and double all measured PSA values during treatment.
This is a monitoring rule derived from PSA suppression, not an efficacy claim.
Use a 4-8 week finasteride overlap when transitioning to dutasteride; assess treatment efficacy for at least 12 months.
This scopes the timing guidance to transition management and hair-response assessment, not controlled comparative efficacy.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.